Cargando…
Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation
Ampullary adenocarcinoma is a rare malignancy that lacks standard systemic treatment. We describe a case of recurrent metastatic ampullary adenocarcinoma of the pancreaticobiliary subtype treated with nanoparticle albumin-bound (nab)-paclitaxel and gemcitabine as first-line treatment. This report al...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452745/ https://www.ncbi.nlm.nih.gov/pubmed/37626821 http://dx.doi.org/10.3390/biomedicines11082326 |
_version_ | 1785095748027678720 |
---|---|
author | Linscott, Maryknoll P. Markus, Havell Sennett, Mackenzie Abendroth, Catherine Yee, Nelson S. |
author_facet | Linscott, Maryknoll P. Markus, Havell Sennett, Mackenzie Abendroth, Catherine Yee, Nelson S. |
author_sort | Linscott, Maryknoll P. |
collection | PubMed |
description | Ampullary adenocarcinoma is a rare malignancy that lacks standard systemic treatment. We describe a case of recurrent metastatic ampullary adenocarcinoma of the pancreaticobiliary subtype treated with nanoparticle albumin-bound (nab)-paclitaxel and gemcitabine as first-line treatment. This report also highlights the molecular profile of the ampullary adenocarcinoma and circulating tumor DNA (ctDNA). This is a case of pancreaticobiliary ampullary adenocarcinoma in a 67-year-old woman who initially presented with painless jaundice. Endoscopic and imaging evaluation revealed biliary ductal dilation secondary to an ampullary mass. Pathology confirmed the diagnosis of ampullary adenocarcinoma of the pancreaticobiliary subtype. She underwent surgical resection of the tumor, followed by adjuvant chemotherapy with gemcitabine and capecitabine. The tumor subsequently recurred in the liver. She received palliative chemotherapy with nab-paclitaxel and gemcitabine, resulting in an objective tumor response for 14 months. Molecular profiling of the tumor and ctDNA revealed a novel MATN2-RSPO RNA fusion and a novel NTRK3 mutation, respectively. Our report suggests that long-term durable response can be achieved in metastatic pancreaticobiliary ampullary adenocarcinoma using nab-paclitaxel and gemcitabine. Molecular profiling of the tumor identified a novel R-Spondin2 RNA fusion and NTRK3 mutation that can be potentially targeted for treatment. |
format | Online Article Text |
id | pubmed-10452745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104527452023-08-26 Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation Linscott, Maryknoll P. Markus, Havell Sennett, Mackenzie Abendroth, Catherine Yee, Nelson S. Biomedicines Case Report Ampullary adenocarcinoma is a rare malignancy that lacks standard systemic treatment. We describe a case of recurrent metastatic ampullary adenocarcinoma of the pancreaticobiliary subtype treated with nanoparticle albumin-bound (nab)-paclitaxel and gemcitabine as first-line treatment. This report also highlights the molecular profile of the ampullary adenocarcinoma and circulating tumor DNA (ctDNA). This is a case of pancreaticobiliary ampullary adenocarcinoma in a 67-year-old woman who initially presented with painless jaundice. Endoscopic and imaging evaluation revealed biliary ductal dilation secondary to an ampullary mass. Pathology confirmed the diagnosis of ampullary adenocarcinoma of the pancreaticobiliary subtype. She underwent surgical resection of the tumor, followed by adjuvant chemotherapy with gemcitabine and capecitabine. The tumor subsequently recurred in the liver. She received palliative chemotherapy with nab-paclitaxel and gemcitabine, resulting in an objective tumor response for 14 months. Molecular profiling of the tumor and ctDNA revealed a novel MATN2-RSPO RNA fusion and a novel NTRK3 mutation, respectively. Our report suggests that long-term durable response can be achieved in metastatic pancreaticobiliary ampullary adenocarcinoma using nab-paclitaxel and gemcitabine. Molecular profiling of the tumor identified a novel R-Spondin2 RNA fusion and NTRK3 mutation that can be potentially targeted for treatment. MDPI 2023-08-21 /pmc/articles/PMC10452745/ /pubmed/37626821 http://dx.doi.org/10.3390/biomedicines11082326 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Linscott, Maryknoll P. Markus, Havell Sennett, Mackenzie Abendroth, Catherine Yee, Nelson S. Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title | Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title_full | Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title_fullStr | Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title_full_unstemmed | Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title_short | Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel R-Spondin2 RNA Fusion and NTRK3 Mutation |
title_sort | nab-paclitaxel and gemcitabine as first-line treatment of metastatic ampullary adenocarcinoma with a novel r-spondin2 rna fusion and ntrk3 mutation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452745/ https://www.ncbi.nlm.nih.gov/pubmed/37626821 http://dx.doi.org/10.3390/biomedicines11082326 |
work_keys_str_mv | AT linscottmaryknollp nabpaclitaxelandgemcitabineasfirstlinetreatmentofmetastaticampullaryadenocarcinomawithanovelrspondin2rnafusionandntrk3mutation AT markushavell nabpaclitaxelandgemcitabineasfirstlinetreatmentofmetastaticampullaryadenocarcinomawithanovelrspondin2rnafusionandntrk3mutation AT sennettmackenzie nabpaclitaxelandgemcitabineasfirstlinetreatmentofmetastaticampullaryadenocarcinomawithanovelrspondin2rnafusionandntrk3mutation AT abendrothcatherine nabpaclitaxelandgemcitabineasfirstlinetreatmentofmetastaticampullaryadenocarcinomawithanovelrspondin2rnafusionandntrk3mutation AT yeenelsons nabpaclitaxelandgemcitabineasfirstlinetreatmentofmetastaticampullaryadenocarcinomawithanovelrspondin2rnafusionandntrk3mutation |